手机东方财富网是东方财富网的手机门户网站,为亿万用户打造一个手机联通世界的超级平台,提供7*24小时全面及时的财经中文资讯,内容覆盖国内外突发事件、股市资讯、全球新闻、产业资讯、实用信息等。手机东方财富网触屏版 - eastmoney.com
Seres Therapeutics(纳斯达克:MCRB) Benzinga01/16 20:05 新闻稿:Seres Therapeutics宣布收到与VOWSt销售相关的预期5000万美元的分期付款 Seres Therapeutics今天宣布收到了与公司之前宣布将其VOWSt业务出售给雀巢公司(Société des Produits Nestlé S.A及其某些附属公司,即雀巢健康科学)相关的5000万美元分期...
Seres Therapeutics(纳斯达克:MCRB) Benzinga01/16 20:05 新闻稿:Seres Therapeutics宣布收到与VOWSt销售相关的预期5000万美元的分期付款 Seres Therapeutics今天宣布收到了与公司之前宣布将其VOWSt业务出售给雀巢公司(Société des Produits Nestlé S.A及其某些附属公司,即雀巢健康科学)相关的5000万美元分期...
Seres Therapeutics, Inc. Common Stock (MCRB) Real-Time 本页面每 30 秒钟刷新一次。 最新更新数据 Mar 14, 2025 09:32 AM ET*Today’s High/Low is only updated during regular trading hours; and does not include trades occurring in pre-market or after-hours....
Seres Therapeutics Inc的表現 攤薄每股盈餘(TTM) -3.114 比去年同期的收入增長 -93.4% 比去年同期的收益增長 0% 邊際利潤 -20.2% 關於Seres Therapeutics Inc Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to funct...
Seres Therapeutics公司计划将发行的资金用于其在研药物SER-109美国市场的商业化事宜和生产,包括扩大长期生产能力、推进其在欧盟市场的临床开发以及其他一般运营用途。 原文链接: https://www.biospace.com/article/releases/seres-therapeutics-announces-1...
Seres Therapeutics公司计划将发行的资金用于其在研药物SER-109美国市场的商业化事宜和生产,包括扩大长期生产能力、推进其在欧盟市场的临床开发以及其他一般运营用途。 原文链接: https://www.biospace.com/article/releases/seres-therapeutics-announces-100-million-registered-direct-offering-of-common-stock/ ...
Seres Therapeutics (MCRB) stock risk factors, discover the 63 risks reported by Seres Therapeutics and see why Finance & Corporate is the top risk category.
2, 2023-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million. Third quarter VOWST commercial results show strong continued ...
“I am thrilled to join Seres as it extends its leadership position in the emerging microbiome therapeutics area,” said DesRosier. “Seres is performing truly innovative research to develop important new therapies for patients with serious diseases, in a whole new area o...